- Home
- TTOO vs CMRX Comparison
TTOO vs CMRX Comparison
Compare TTOO & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTOO
- CMRX
- Stock Information
- Founded
- TTOO 2006
- CMRX 2000
- Country
- TTOO United States
- CMRX United States
- Employees
- TTOO N/A
- CMRX N/A
- Industry
- TTOO Medical/Dental Instruments
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- TTOO Health Care
- CMRX Health Care
- Exchange
- TTOO Nasdaq
- CMRX Nasdaq
- Market Cap
- TTOO 36.4M
- CMRX 77.0M
- IPO Year
- TTOO 2014
- CMRX 2013
- Fundamental
- Price
- TTOO $0.97
- CMRX $0.93
- Analyst Decision
- TTOO Hold
- CMRX Strong Buy
- Analyst Count
- TTOO 1
- CMRX 1
- Target Price
- TTOO $5.00
- CMRX $11.00
- AVG Volume (30 Days)
- TTOO 710.5K
- CMRX 119.4K
- Earning Date
- TTOO 11-13-2024
- CMRX 11-08-2024
- Dividend Yield
- TTOO N/A
- CMRX N/A
- EPS Growth
- TTOO N/A
- CMRX N/A
- EPS
- TTOO N/A
- CMRX N/A
- Revenue
- TTOO $7,164,000.00
- CMRX $144,000.00
- Revenue This Year
- TTOO $50.31
- CMRX $3,040.12
- Revenue Next Year
- TTOO $117.92
- CMRX N/A
- P/E Ratio
- TTOO N/A
- CMRX N/A
- Revenue Growth
- TTOO N/A
- CMRX N/A
- 52 Week Low
- TTOO $0.90
- CMRX $0.75
- 52 Week High
- TTOO $8.38
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- TTOO 18.34
- CMRX 60.78
- Support Level
- TTOO $0.90
- CMRX $0.80
- Resistance Level
- TTOO $1.86
- CMRX $0.98
- Average True Range (ATR)
- TTOO 0.15
- CMRX 0.05
- MACD
- TTOO -0.00
- CMRX 0.01
- Stochastic Oscillator
- TTOO 5.72
- CMRX 83.33
About TTOO T2 Biosystems Inc.
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.